Tumor marker detection reagents play an important role in cancer screening, auxiliary diagnosis, and treatment efficacy monitoring, but the accuracy of their test results is affected by various factors. To ensure the reliability of test results, the following precautions must be strictly observed during clinical use and patient cooperation.
I. Standardization of Sample Collection and Processing
Tumor marker testing typically relies on blood, urine, or other body fluid samples. Therefore, standardization of sample collection directly affects the results. Avoid strenuous exercise, high-fat diets, or alcohol before blood collection, as these factors may cause transient elevations in certain markers (such as CEA and CA19-9). Fasting blood collection (usually after 8-12 hours of fasting) is suitable for most tests, but specific requirements should be followed in the reagent instructions. Samples should be submitted for testing as soon as possible after collection to avoid degradation caused by prolonged storage, especially for temperature-sensitive markers (such as PSA).
II. Applicability of Detection Methods
Different tumor marker detection methods (such as chemiluminescent immunoassays and enzyme-linked immunosorbent assays) have varying sensitivities and specificities. Clinical selection should be tailored to the patient's specific circumstances. For example, AFP (alpha-fetoprotein) is commonly used for liver cancer screening, but false positives can occur in patients with cirrhosis, necessitating a comprehensive assessment based on imaging studies. Furthermore, batch-to-batch variability in reagents can affect the comparability of results. Laboratories should regularly calibrate equipment and use quality control materials to monitor test stability.
III. Limitations of Result Interpretation
An elevated tumor marker does not necessarily indicate cancer. Inflammation, benign tumors, or physiological conditions (such as elevated AFP during pregnancy) can all lead to false positives. Conversely, some patients with early-stage cancer may still have marker levels within the normal range, so a negative result for a single marker does not completely rule out cancer. In clinical practice, multiple markers are often tested in combination (such as CEA, CYFRA21-1, and NSE for lung cancer), combined with comprehensive analysis based on imaging and pathological findings.
IV. Patient Education and Follow-up
Patients should understand the auxiliary nature of tumor marker testing to avoid excessive anxiety or neglect due to fluctuating results. For patients undergoing treatment, regular monitoring of marker dynamics is more important than a single value. For example, persistently elevated CEA levels after surgery may indicate recurrence. Healthcare professionals must clearly explain the purpose, limitations, and next steps of testing to patients to ensure informed decision-making.
In short, the use of tumor marker testing reagents must strictly adhere to standards, with professional oversight from sample collection to result interpretation required to fully realize their value in cancer management.